AZD-2327
(Redirected from AZD2327)
AZD-2327[edit | edit source]
AZD-2327 is a chemical compound that was developed as a potential therapeutic agent for the treatment of anxiety and depression. It is classified as a serotonin receptor agonist, specifically targeting the 5-HT1A receptor.
Pharmacology[edit | edit source]
AZD-2327 acts primarily as a selective agonist at the 5-HT1A receptor, which is a subtype of the serotonin receptor found in the central nervous system. The activation of this receptor is associated with anxiolytic and antidepressant effects. The compound was designed to exploit these properties to provide therapeutic benefits in the treatment of mood disorders.
Mechanism of Action[edit | edit source]
The mechanism of action of AZD-2327 involves the stimulation of the 5-HT1A receptor, which leads to increased serotonin neurotransmission. This receptor is involved in the regulation of mood, anxiety, and stress responses. By activating the 5-HT1A receptor, AZD-2327 is thought to enhance serotonergic activity, thereby exerting its potential therapeutic effects.
Development and Research[edit | edit source]
AZD-2327 was developed by AstraZeneca, a pharmaceutical company known for its research in the field of neuroscience. The compound underwent preclinical and early clinical trials to evaluate its efficacy and safety profile. However, despite initial promising results, the development of AZD-2327 was eventually discontinued.
Clinical Trials[edit | edit source]
During its development, AZD-2327 was subjected to various phases of clinical trials. These trials aimed to assess its effectiveness in reducing symptoms of anxiety and depression, as well as to determine its safety and tolerability in humans. Although the compound showed some potential, it did not progress beyond early-stage trials.
Potential Applications[edit | edit source]
While AZD-2327 is no longer in active development, its study has contributed to the understanding of serotonin receptor agonists and their role in treating mood disorders. The research conducted on AZD-2327 has provided insights into the design of future compounds targeting the 5-HT1A receptor for therapeutic purposes.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
